Rank 49 • Biotech & Discovery
AbCellera
Discovers and develops antibody-based medicines using a high-throughput microfluidic and machine learning platform.
Visit website- Signal Score
- 88.2
- Total raised
- $350M
- Stage
- Public
- Founded
- 2012
- Headquarters
- Vancouver, Canada
- Region
- North America
Their signal
Known for rapidly co-developing key COVID-19 antibody treatments, Abcellera continues to land high-value multi-target discovery alliances with leading global biopharmaceutical companies.
Signal Score 88.2editorial estimate, see how it is built
Total raised, quality of investors and recency of the last round.
Revenue trajectory, customer count, hiring and market pull.
Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.
Founder track record, clinical depth on the bench and technical leadership.
Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.
Also in Biotech & Discovery
Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.